We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
KemPharm Inc | NASDAQ:KMPH | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5.81 | 5.79 | 5.88 | 0 | 01:00:00 |
Delaware
|
001-36913
|
20-5894398
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
1180 Celebration Boulevard, Suite 103,
Celebration, FL
|
34747 | |
(Address of Principal Executive Offices)
|
(Zip Code)
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.0001 per share
|
ZVRA
|
The Nasdaq Stock Market LLC
(Nasdaq Global Select Market)
|
●
|
to elect three Class II directors to the Company’s board of directors to hold office until the 2026 annual meeting of stockholders;
|
|
●
|
to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023; and
|
|
●
|
to vote on the Mangless Proposal to adopt a resolution that would repeal any provision of the Company’s Amended and Restated Bylaws in effect at the time of the Annual Meeting that was not included in the Company’s Amended and Restated Bylaws in effect as of January 1, 2023 (other than the change of the Company’s name).
|
For
|
Against
|
Abstentions
|
Broker Non-Votes
|
||
2.
|
Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023.
|
16,255,418
|
326,824
|
941,175
|
-
|
For
|
Against
|
Abstentions
|
Broker Non-Votes
|
||
3.
|
The Mangless Proposal, to adopt a resolution that would repeal any provision of the Company’s Amended and Restated Bylaws in effect at the time of the Annual Meeting that was not included in the Company’s Amended and Restated Bylaws in effect as of January 1, 2023 (other than the change of the Company’s name).
|
14,491,565
|
2,913,126
|
118,726
|
-
|
|
|
Zevra Therapeutics, Inc.
|
|
|
|
|
|
Date: April 26, 2023
|
|
By:
|
/s/ R. LaDuane Clifton
|
|
|
|
R. LaDuane Clifton, CPA
|
|
|
|
Chief Financial Officer, Secretary and Treasurer
|
1 Year KemPharm Chart |
1 Month KemPharm Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions